Aier Eye Hospital invests ¥100m in low-risk wealth management

Aier Eye Hospital Group Co., Ltd. has announced the implementation of its cash management plan, utilizing a portion of its idle self-owned funds. Following approval from its board of directors and supervisors, the company has allocated up to ¥1.5 billion to purchase highly secure, liquid, and low-risk wealth management products. This initiative aims to improve capital utilization and generate investment returns for the company and its shareholders, without impacting daily operations.

As part of this plan, Aier Eye Hospital recently invested ¥100 million in the "Bank of China Wealth Management - (14-Day) Minimum Holding Period Fixed Income Wealth Management Product No. 2 A," an RMB-denominated product with a low-to-medium risk profile. The product's performance benchmark is 2.35%, with interest accruing from December 4, 2025, and available for redemption after December 17, 2025. This specific investment is funded by the company's self-owned funds.

The company's risk control measures include strict adherence to prudent investment principles, focusing solely on low-risk investment varieties, and excluding stocks or derivatives. The financial center will continuously monitor product performance and address any potential risks. Additionally, the internal audit department will oversee fund usage and custody, while the board of supervisors and independent directors will conduct regular inspections. Information regarding the purchase and performance of wealth management products will be disclosed in periodic reports, in accordance with Shenzhen Stock Exchange regulations.